Ceprotin Treatment Registry

• Protein C Concentrate (Human) (Biological), also known as Ceprotin: Commercially available Ceprotin will be prescribed, obtained and administered by the investigator according to local standard of care.

Primary outcomes

• Medical diagnoses associated with Ceprotin treatment [2 to 5 years, or until the Registry is terminated]
• Ceprotin treatment regimens [2 to 5 years, or until the Registry is terminated]
• Safety information based on all serious adverse events (SAEs), related SAEs and related non-serious adverse events (AEs) [2 to 5 years, or until the Registry is terminated]

Secondary outcomes

• Treatment outcomes categorized by medical diagnosis [2 to 5 years, or until the Registry is terminated]: Evidence of halting or reversal of coagulopathy or thrombosis, end-organ damage, limb sparing, Length of Hospital Stay (LOS), and mortality
• CEPROTIN use and treatment outcomes in pregnancy, labor and delivery, surgery and invasive procedures, different age groups, and, in the presence of pre-existing renal and/or hepatic dysfunction [2 to 5 years, or until the Registry is terminated]

Sex: All

Inclusion Criteria:

Participants for whom CEPROTIN therapy has been indicated and meeting the following criteria may be enrolled in this study:

* Signed and dated informed consent from either the participant or the participant's legally authorized representative prior to enrollment, as applicable
* Males and females of any age, including neonates, children, adolescents and adults
* Participant who received CEPROTIN or is initiating/receiving CEPROTIN treatment

Exclusion Criteria:

* None

• Study Director, Study director, Takeda